Category - Developments

Developments

MacroGenics doses first patient in Phase 2/3 gastroesophageal cancer trial

MacroGenics (NASDAQ:MGNX) dosed the first patient in its Phase 2/3 MAHOGANY clinical trial of margetuximab for the treatment of HER2-positive gastric cancer (GC) or gastroesophageal junction (GEJ) cancer. The trial will...

October 25, 2019

Developments

Fresenius gets FDA breakthrough device designation for hemodialysis system

Fresenius Medical Care (NYSE:FMS) received FDA breakthrough device designation for its hemodialysis system, which is being developed for the prevention of blood clotting without the use of blood thinner medication. Many...

October 24, 2019

Developments

SpringWorks Therapeutics doses first patient in Phase 2b mirdametinib trial

SpringWorks Therapeutics (NASDAQ:SWTX) dosed the first patient in its Phase 2b trial evaluating mirdametinib in children and adults with neurofibromatosis type 1 (NF1)-associated plexiform neurofibromas (PN). NF1 is a...

October 24, 2019

Developments

Zosano Pharma begins enrollment in Phase 2/3 cluster headache trial

Zosano Pharma (NASDAQ:ZSAN) has begun enrolling cluster headache patients in its Phase 2/3 study evaluating C213 for the acute treatment of cluster headache. C213 consists of the same formulation of zolmitriptan as the...

October 24, 2019

Developments

Zealand Pharma acquires Encycle Therapeutics

Zealand Pharma (NASDAQ:ZEAL) of Denmark has acquired Encycle Therapeutics, a closely-held biotech company in Toronto, exploiting a unique platform technology that enables the rapid synthesis of macrocyclic peptides...

October 24, 2019

Developments

Liminal BioSciences to present preclinical findings at kidney conference

Liminal BioSciences (TSX:LMNL) and its collaborators will present preclinical findings on a novel therapeutic approach to the treatment of inflammatory and fibrosis-related kidney diseases at the American Society of...

October 24, 2019

Developments

Bausch + Lomb licenses Clearside’s XIPERE for macular edema associated with uveitis

An affiliate of Bausch Health Companies (NYSE,TSX:BHC) has acquired an exclusive license for the commercialization and development of XIPERE in the U.S. and Canada from Clearside Biomedical (NASDAQ:CLSD). XIPERE is a...

October 23, 2019

Developments

Hepion to present CRV431’s potential in liver fibrosis at NASH summit

Hepion Pharmaceuticals’ (NASDAQ:HEPA) CSO, Dr. Daren Ure, will discuss the potential of the company’s lead candidate, CRV431, as a treatment for non-alcoholic steatohepatitis (NASH) at the third annual NASH summit. Dr...

October 23, 2019

Developments

Zenabis in cannabis cultivation accord with Tantalus Labs

Zenabis Global (TSX:ZENA) entered into an agreement with Tantalus Labs to grow and harvest cannabis plants from clones provided by Tantalus. The plants will be grown and harvested at the Zenabis Langley plant. Tantalus...

October 23, 2019

Developments

KemPharm presents patient-friendly dosing data for KP415 in ADHD

KemPharm (NASDAQ:KMPH) presented study results demonstrating the ability of KP415 to be administered without regard to food and via alternative dosing methods at the annual American Academy of Child and Adolescent...

October 23, 2019

Category - Developments

MacroGenics doses first patient in Phase 2/3 gastroesophageal cancer trial

Fresenius gets FDA breakthrough device designation for hemodialysis system

SpringWorks Therapeutics doses first patient in Phase 2b mirdametinib trial

Zosano Pharma begins enrollment in Phase 2/3 cluster headache trial

Zealand Pharma acquires Encycle Therapeutics

Liminal BioSciences to present preclinical findings at kidney conference

Bausch + Lomb licenses Clearside’s XIPERE for macular edema associated with uveitis

Hepion to present CRV431’s potential in liver fibrosis at NASH summit

Zenabis in cannabis cultivation accord with Tantalus Labs

KemPharm presents patient-friendly dosing data for KP415 in ADHD

Follow Us

Subscribe

General

More

Subscribe